Christel Menet

Christel joined Confo Therapeutics as CSO in 2016.

She was one of the first chemists to join Galapagos and later became Director of Medicinal Chemistry. Under her leadership, Galapagos discovered filgotinib, which has since completed Phase III clinical testing and is primarily being tested for rheumatoid arthritis, among other indications. Prior to Galapagos, Christel worked at Faust Pharmaceuticals (now Domain Therapeutics), a biotechnology company specializing in GPCR drug discovery. She is an inventor on over 20 patent applications and brings over 18 years of R&D experience to Confo.

Christel completed a PhD in Organic Chemistry at the University of Manchester (UK) in the lab of Prof Jonathan Clayden.